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Abstract
Background
We performed a systematic screening of colorectal cancer (CRC) tissues to investigate
whether mismatch repair (MMR) status and ERCC1 protein expression could be predictive
of clinical outcomes for these patients following the recommendation of The Evaluation of
Genomic Applications in Practice of Prevention (EGAPP).
Methods
The expression of four MMR genes and ERCC1 were assessed by immunohistochemistry
(IHC) from cancer tissue samples of 2233 consecutive CRC patients.
Results
We observed that most CRC patients with a proficient MMR (pMMR) status tended to have
simultaneous ERCC1 protein expression (P< 0.001). Stage III CRC patients with deficient
MMR (dMMR) had higher prognoses than the same stage patients with pMMR (DFS: 74%
vs 65%, P = 0.04; OS: 79% vs 69%, P = 0.04). Here, dMMR is also associated with poorer
survival for stage II patients after chemotherapy (DFS: 66% vs 78%, P = 0.04). Stage II and
III patients that were shown to express ERCC1 protein had higher DFS and OS than those
that were deficient in expression (stage II, DFS: 83% vs 70%, P = 0.006; OS 85% vs 73%,
P = 0.02. Stage III, DFS: 67% vs56%, P = 0.03; OS: 71% vs 57%, P = 0.04).
Conclusions
Our results indicate that dMMR appeared to predictive of a survival benefit for stage III CRC
patients. We also found the determination of ERCC1 expression to be useful for predicting
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DFS or OS for stage II and III CRC patients. In addition, the expression of MMR genes and
ERCC1 showed a significant relationship.
Introduction
In 2009 the Evaluation of Genomic Applications in Practice of Prevention (EGAPP) recom-
mended screening MMR status for all newly diagnosed patients with colorectal cancer [1].
MMR corrects mismatched nucleotides and insertion-deletion loops (IDLs) in DNA caused by
polymerase errors, chemical modifications, and recombination between heterologous DNA
sequences [2]. MMR proteins also act as sensors to activate DNA damage checkpoints in
response to alkylating agents and other DNA-damaging agents [3]. Thus, changes in MMR sta-
tus could have significant impact on cancer onset and progression including CRC.
CRCs with dMMR have distinct clinical and pathological features that commonly include
proximal colon predominance, poor differentiation and increased numbers of lymph nodes
with metastases[4]. MMR status is increasingly used to guide clinical management. Stage II
patients with dMMR have a better prognosis and may actually be harmed by 5-FU treatment
[5]. Multiple studies have shown that CRCs with dMMRhave a better stage-adjusted survival
compared with pMMR cancers. However, these data are largely from retrospective studies
or focused on Lynch syndrome [6,7,8]. Molecular studies comparing CRCs with early and
advanced stages have been rare.
Another pathway of DNA repair to operate on specific types of damaged DNA is the nucle-
otide-excision repair (NER) pathway [9]. ERCC1 is a key molecule in the NER pathway, which
is responsible for repairing DNA adducts induced by platinum drugs [10,11]. It was reported
that the ERCC1 expression was predictive for the sensitivity of oxaliplatin in colorectal cell
lines [12]. Based on this evidence, several clinical studies have been conducted with the aim of
relating ERCC1 tumor levels with response to oxaliplatin, but these results are still controver-
sial. Moreover, all of these data were generated in the metastatic setting [13,14,15]. Although
ERCC1 has a role as a prognostic marker in non–small-cell lung cancer (NSCLC)[16], for
patients with CRC, the definite prognostic value of ERCC1 expression has not been established
yet. And there is no study to explore the relationship between MMR status and ERCC1
expression.
Following the recommendations by EGAPP, systematic IHC screening for microsatellite
instability of patients operated to remove their primary tumors for CRC has been assessed in
our institute since 2011. At the same time, our group initiated testing for ERCC1 expression,
in particular with immunohistochemistry as part of a standard fast routine test. For this report,
we took advantage of this available data to analyze the detection rate, relationship, prognostic
and predictive significance of MMR status and ERCC1 expression tested for all stages of CRC
disease in China.
Patients and methods
Patients
The ethics committee of Sun Yat-sen University Cancer Center approved this study and
informed consent for all patients was obtained at the beginning of the study. A total of 4500
histologically confirmed CRC patients were recruited after operation from Sun Yat-sen Uni-
versity cancer center between May 2011 and May 2016. All patients were of chinese origin.
The clinical and family history of each of these patients was also reviewed. In our study, we
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analyzed the MMR status in sporadic CRC, while the dMMR frequency tends to be high in
CRC patients with family history, especially for CRC patients with Lynch syndrome (LS). We
also excluded patients with severe complications, multiprimary cancer and death not due to
tumor-related reasons, in order to focus on the CRC-related survival analysis. Finally, 2233
cases were selected for analysis after application of strict exclusion criteria as outlined: age less
than 18 years and older than 85 years (261 cases), severe complication (62 cases), multiprimary
cancer, synchronous and metachronous CRC (135 cases), family history (first-degree and sec-
ond-degree relatives had any kind of cancer) (258 cases), familial adenomatous polyposis (51
cases), incomplete follow-up records (1747 cases), death not due to tumor-related reason (47)
were not included in the study. The primary tumor site was categorized as either proximal
colon if the tumor was located above the splenic flexure or distal colon if it was located at or
below the splenic flexure and rectum. The median follow-up for the surviving patients used in
this study was 4.3 years. The patients’ information can be seen in the supporting information
(S1 Data).
Treatment and follow-up
Stage I (T1–2 N0) and stage II (T3–4 N0) CRC patients without high-risk clinical features (e.g.
T4 stage, bowel perforation or clinical bowel obstruction, inadequate lymph node sampling,
poorly differentiated histology) were treated with radical surgery or endoscopic removal of the
tumor alone. Stage II (T3–4 N0) CRC patients with high-risk clinical features were recom-
mended to receive XELODA/mFOLFOX/XELOX regimen treatments. Stage III (Tx N1–2)
patients were to receive radical surgery and 12 cycles of adjuvant mFOLFOX/XELOX regimen
treatment within a 6-month period. All stage IV (Tx Nx M1) patients received palliative sur-
gery or radical surgery. The first-line treatment for Stage IV CRC was the mFOLFOX/FOL-
FIRI regimen. Eighty-nine patients with rectal cancer also received neo-chemoradiotherapy.
Responses were evaluated in accordance with the RECIST guidelines. After surgery, tumor
recurrence was detected by physical examination, serum carcinoembryonic antigen (CEA)
assay, and abdominal and thoracic imaging monitoring analyzed every 3–6 months for the
first 3 years, every 6 months for the following 2 years and then once annually for those patients
surviving beyond the 5 year time point. The duration of follow-up was defined as the time
between surgery and disease recurrence, death or last hospital contact (scheduled follow-up or
telephone contact). The cutoff date for this analysis was May 2016.
Screening
Blocks of formalin-fixed, paraffin-embedded adenocarcinoma tissue comprising an area of
normal colorectal mucosa adjacent to the tumor were selected in each case. Cases with com-
plete nuclear loss of expression in invasive tumor cells with retained expression in inflamma-
tory cells and/or adjacent normal tissue as positive controls were considered MMR deficient
or ERCC1 negative expression. Staining was performed using the following primary anti-
bodies: mouse anti-human MLH1 (dilution 1:50, clone OTI1C1, zhongshan jiqiao, Beijing),
rabbit anti-human MSH2 (dilution 1:200, clone ZA0622, zhongshan jiqiao, Beijing, mouse
anti-human MSH6 (dilution 1:100, clone OTI5D1, zhongshan jiqiao, Beijing), mouse anti-
human PMS2 (dilution 1:50, clone OTI2G5, zhongshan jiqiao, Beijing), and mouse anti-
human ERCC1 (dilution 1:200, clone OTI1A3, zhongshan jiqiao, Beijing). Whole tissue sec-
tions were read separately by two pathologists blinded to the patients’ clinical characteristics.
Discordant cases were reviewed by a supplementary pathologist to reach a consensus. Illustra-
tive immunostainings were showed in Fig 1.
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Statistical analyses
Data were described as frequencies (percentages). Differences in distributions between the vari-
ables examined were assessed with the Χ2 or the Fisher’s exact test. The primary end point was
DFS, defined as the time between the date of surgery and the first event (local or distant disease
recurrence) or progression-free survival (PFS), calculated from the start of surgery until clinical
or radiological progression. Patients who were alive and relapse free at the last contact were cen-
sored at the last follow-up date. Overall survival was defined as the time elapsed from the date of
surgery until tumor-induced death. Surviving patients were censored on the last follow-up date.
Median follow-up and the 95% CI were calculated using the reverse Kaplan–Meier method.
Survival curve was estimated with the Kaplan–Meier method and compared using the log-rank
test. Univariate and multivariable Cox proportional hazards models were used to explore the
association of MMR status, ERCC1 expression, location, age, stage, differentiation grade and
gender. The score and likelihood ratio test P values were used to test the statistical significance
of each covariate in the univariate and multivariable Cox models, respectively. All statistical
tests were two-sided, and P values less than or equal to 0.05 were considered statistically signifi-
cant. Statistical analyses were performed using SPSS software.
Results
Of the 2233 patients evaluated, 232 were found to have dMMR with an overall prevalence of
10.4%. 208 were found to have negative ERCC1 expression with prevalence of 9.3%. Detailed
clinicopathological information for all patients is shown in Table 1.
Frequency of MMR status and expression of ERCC
A total of 2001 (89.6%) CRC specimens showed retained expression of MLH1, MSH2, MSH6
and PMS2 in tumor cells. In comparison, loss of expression in at least one of the four MMR
genes occurred only in 232 of 2233 patients (10.4%). The distribution of loss of expression of
the MMR genes was as following: combined MLH1/PMS2 loss (n = 79; 34.1%), combined
MSH2/MSH6 loss (n = 33; 14.2%), combined MLH1/MSH2/MSH6/PMS2 loss (n = 7; 3.0%),
combined MLH1/MSH6 loss (n = 4; 1.7%), combined MLH1/MSH6/PMS2 loss (n = 5; 2.2%),
combined MLH1/MSH2/PMS2 loss (n = 5; 2.2%), isolated MLH1 loss (n = 17; 7.3%), isolated
PMS2 loss (n = 12; 5.2%), isolated MSH2 loss (n = 16; 6.9%), isolated MSH6 loss (n = 54;
23.3%). We stratified the clinical characteristics of the study population by MMR status. The
dMMR vs pMMR CRC were more likely to be stage IIA (16.6%) vs others (stage I: 9.1%, stage
IIB: 8.0%, stage IIC: 19.0%, stage IIIA: 10.9%, stage IIIB: 8.4%, stage IIIC: 11.9%, stage IVA:
5.3%, stage IVB: 4.3%, P<0.001), right colon (22.5%) vs left colon (7.4%) and rectum (6.2%)
Fig 1. Illustrative immunostainings. A: MLH1(+) and (-); B:MSH2 (+) and (-); C: MSH6 (+) and (-); D: PMS2
(+) and (-); E: ERCC1 (+) and (-).
https://doi.org/10.1371/journal.pone.0181615.g001
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(P< 0.001), from men (11.6%) vs women (8.7%) (P = 0.031), and poor or undifferentiated
(23.6%) vs well or moderate differentiation (9.6%) (P< 0.001), young age (20–39 years old,
13.8%) vs old age (40–59 years, 12.2%; 60–85 years old, 8.3%; P = 0.001), ERCC1 negative
(23.1%) vs ERCC1 positive (9.1%) (P< 0.001). The multi-analysis results are shown in Table 2.
In all, 208 cases (9.3%) had negative ERCC1 tumors and 2015 cases (90.7%) had positive
tumors. Gender, age, location, stage and pathological differentiation showed no statistic differ-
ence in univariate Cox analysis (P>0.05) for ERCC1 expression.
Assessment of MMR as prognostic marker
MMR status provided prognostic information in CRC patients. Patients with stage III CRC
with dMMR tumors showed a statistically significant improvement in DFS (74%) and OS
Table 1. Clinicopathological information for all patients.
Characteristic MMR status (n/%) P value ERCC1 expression (n/%) P value
dMMR (232/10.4) pMMR (2001/89.6) negative (208/9.3) positive (2025/90.7)
Gender 0.031 0.613
Male
Female
152 (6.8)
80 (3.6)
1164(52.1)
837(37.5)
126 (5.6)
82 (3.7)
1190 (53.3)
835 (37.4)
Age 0.001 0.872
20–39 years
40–59 years
60–85 years
26 (1.2)
125 (5.6)
81(3.6)
162 (7.3)
899 (40.3)
940(42.1)
13 (0.6)
103 (4.6)
92 (4.1)
175 (7.8)
921 (41.2)
929 (41.6)
Pathology 0.002 0.194
G1
G2
G3
Mucinous
Signet-ring
21 (0.9)
181 (8.1)
2 (0.1)
26 (1.2)
2 (0.1)
83 (3.7)
1821 (81.5)
16 (0.7)
69 (3.1)
12 (0.5)
6 (0.3)
188 (8.4)
1 (0.0)
11 (0.5)
2 (0.1)
98 (4.4)
1814 (81.2)
17 (0.8)
84 (3.8)
12 (0.5)
Stage <0.001 0.491
I
IIA
IIB
IIC
IIIA
IIIB
IIIC
IVA
IVB
30 (1.3)
101 (4.5)
18 (0.8)
8 (0.4)
6 (0.3)
37 (1.7)
11 (0.5)
14 (0.6)
7 (0.3)
301 (13.5)
509 (22.8)
207 (9.3)
34 (1.5)
49 (2.2)
415 (18.6)
81 (3.6)
251 (11.2)
154 (6.9)
27 (1.2)
65 (2.9)
24 (1.1)
8 (0.4)
4 (0.2)
33 (1.5)
7 (0.3)
20 (0.9)
20 (0.9)
304 (13.6)
545 (24.4)
201 (9.0)
34 (1.5)
51 (2.3)
419 (18.8)
85 (3.8)
245 (11.0)
141 (6.3)
Location <0.001 0.855
Right colon
Left colon
Rectum
117 (5.2)
55 (2.5)
60 (2.7)
404 (18.1)
685 (30.7)
912 (40.8)
50 (2.2)
64 (2.9)
94 (4.2)
471 (21.1)
676 (30.3)
878 (39.3)
MMR status <0.001 <0.001
dMMR
pMMR
232 (10.4)
0 (0.0)
0 (0.0)
2001 (89.6)
48 (2.1)
160 (7.2)
184 (8.2)
1841 (82.4)
ERCC1 <0.001 <0.001
Negative
positive
48 (2.1)
184 (8.2)
160 (7.2)
1841 (82.4)
208 (9.3)
0 (0.0)
0 (0.0)
2025 (90.7)
Metastasis 0.006 0.028
Yes
No
60 (2.7)
172 (7.7)
699 (31.3)
1302 (58.3)
85 (3.8)
123 (5.5)
674 (30.2)
1351 (60.5)
Live 0.008 0.019
Yes
No
178 (8.0)
54 (2.4)
1366 (61.2)
635 (28.4)
129 (5.8)
79 (3.5)
1415 (63.4)
610 (27.3)
https://doi.org/10.1371/journal.pone.0181615.t001
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(79%), compared with patients with pMMR tumors (DFS 65%; HR: 1.57, 95% CI: 0.85–3.53,
P = 0.04 and OS 69%; HR: 1.74, 95% CI: 0.95–3.20, P = 0.04). This was in contrast to the results
of analysis obtained for stage I patients where no difference in the 3-year DFS (93%) and OS
(93%) was found between dMMR versus patients with pMMR (DFS 94%; HR: 0.01, 95% CI:
0.21–3.94, P = 0.90 and OS 95%; HR: 0.84, 95% CI: 0.19–3.67, P = 0.82). For stage II patients,
we also found no difference in the 3-year DFS (82%) and OS (83%) between the dMMR group
versus the pMMR group (DFS 80%; HR: 0.86, 95% CI: 0.56–1.33, P = 0.51 and OS 82%; HR:
0.91, 95% CI: 0.57–1.43, P = 0.66). Finally, we found no difference in the 3-year DFS (12%)
and OS (18%) for stage IV patients between the dMMR group versus the pMMR group (DFS
10%; HR: 1.11, 95% CI: 0.70–1.76, P = 0.66 and OS 14%; HR: 1.19, 95% CI: 0.74–1.92,
P = 0.47). The survival plots of MMR status are shown in Fig 2.
Assessment of MMR as Predictive Marker for Stage II CRC
The 3-year DFS of stage II patients with chemotherapy and without chemotherapy was 78%
and 84%, respectively (HR: 1.42, 95% CI: 1.03–1.94, P = 0.03). The OS rate between chemo-
therapy group and non-chemotherapy group was 81% and 86%, respectively (HR: 1.46, 95%
CI: 1.04–2.04, P = 0.02), confirming that addition of chemotherapy to treatments for stage II
CRC damages the prognosis within this setting of patients. However, the 3-year DFS was
Table 2. Multi-variate analysis of disease-free survival and overall survival.
95% CI of DFS 95% CI of OS
Variable HR Lower Upper P value HR Lower Upper P value
Age 2.24 2.16 2.34 0.001 2.38 2.36 2.42 <0.001
Gender 1.35 1.28 1.41 0.031 1.41 1.39 1.44 0.032
Stage 3.54 3.19 3.89 <0.001 3.19 3.23 3.85 <0.001
Location 2.25 2.22 2.28 <0.001 1.75 1.66 1.86 0.001
Grade 2.17 2.10 2.14 0.002 2.23 2.07 2.26 0.001
ERCC1 0.79 0.76 0.83 <0.001 0.92 0.91 0.93 <0.001
https://doi.org/10.1371/journal.pone.0181615.t002
Fig 2. The survival plots of MMR status. A: stage I patients; B: stage II patients; C: stage III patients; D: stage IV patients.
https://doi.org/10.1371/journal.pone.0181615.g002
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significantly lower in stage II patients with chemotherapy with dMMR tumors (66%) than in
the same group patients with pMMR tumors (78%, HR: 0.84, 95%CI: 0.47–1.15, P = 0.04).
Despite this finding for DFS, the OS showed no statistical difference in stage II patients with
chemotherapy with dMMR tumor (75%) and in the same group of patients with pMMR
tumors (82%, HR: 0.75, 95%CI: 0.45–1.26, P = 0.28). Also, no difference in the 3-year DFS
(85%) and OS (89%) for stage II patients without chemotherapy between the dMMR group
versus the pMMR group (DFS 83%; HR: 0.86, 95% CI: 0.56–1.33, P = 0.50 and OS 84%; HR:
0.90, 95% CI: 0.57–1.43, P = 0.66). The survival plots of chemotherapy and MMR status are
shown in Fig 3.
Fig 3. The survival plots of chemotherapy and MMR status. A: all stage II patients; B: stage II patients
without chemotherapy; C: stage II patients with chemotherapy.
https://doi.org/10.1371/journal.pone.0181615.g003
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Assessment of ERCC1 as prognostic marker
The group with negative ERCC1 expression showed no statistically significant improvement of
3-year DFS or OS in stage I patients (DFS: 96% vs 93%, HR: 0.60, 95%CI: 0.08–4.46, P = 0.62;
OS: 96% vs 94%, HR: 0.61, 95%CI: 0.08–4.59, P = 0.61). However, in stage II patients, the
3-year DFS and OS in ERCC1 positive group was statistically significantly higher than in
ERCC1 negative group (DFS: 83% vs 70%, HR:1.75, 95%CI: 1.17–2.61, P = 0.006; OS: 85% vs
73%, HR:1.67, 95%CI: 1.09–2.55, P = 0.02). In addition, patients with stage III CRC with posi-
tive ERCC1 tumors also showed a statistically significant improvement in DFS (67%) and OS
(71%), compared to patients with negative ERCC1 tumors (DFS 56%; HR: 1.45, 95% CI: 0.91–
2.29, P = 0.03 and OS 57%; HR: 1.58, 95% CI: 0.9–2.52, P = 0.04). Finally, we found no differ-
ence in the 3-year DFS (12%) and OS (16%) for stage IV patients between the positive ERCC1
group versus the negative group (DFS 8%; HR: 1.06, 95% CI: 0.75–1.51, P = 0.73 and OS 18%;
HR: 0.87, 95% CI: 0.61–1.26, P = 0.47). These associations toward better survival for ERCC1
expression for stage II and III patients versus stage I or IV patients indicate that ERCC1 might
be a useful marker for analysis of CRC disease. The survival plots of ERCC1 expression are
shown in Fig 4.
Discussion
This current study presents a large dataset exploring a role for tumor MMR status and ERCC1
expression with respect to prevalence of CRC and disease outcome in a population of chinese
patients (n = 2233).
Tumors with dMMR usually show complete loss of expression of one or more MMR pro-
tein. Here, all four MMR genes (MLH1, MSH2, MSH6 and PMS2) were analyzed by IHC for
detection. The most frequent MMR gene expression pattern found was the concurrent loss of
MLH1 and PMS2, which accounted for 34.1% of all CRC cases studied in our analysis. The sec-
ond most common pattern found was the isolated loss of the MSH6 gene that accounted for
23.3% of the CRC tumors analyzed and is similar to the result of previous related studies
regarding detection of MMR gene mutations[17,18]. In our study, we excluded patients with
Fig 4. The survival plots of ERCC1 expression. A: stage I patients; B: stage II patients; C: stage III patients; D: stage IV
patients.
https://doi.org/10.1371/journal.pone.0181615.g004
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familial cancer history, which included the high-penetrant Lynch families (those with MLH1
and MSH2 germline alternations), the remaining patients with lesser penetrant LS (those with
MSH6 and PMS2 germline mutations) can be the reason for the high percentage of MSH6 loss
in our study.
In our study, the incidence rate of dMMR tumor was only 10.4%, which is lower than the
published incidence rates (15–25%) of dMMR found for African-American CRCs[19,20] or
15% found for mixed race populations[21]. We found the MMR mutation frequency was sig-
nificantly lower in our study indicating that a significant proportion of CRC in China may
actually follow tumorigenesis pathways distinct from the dMMR CRC progression sequence.
Clearly, this possible heterogeneity could also have implications for CRC prognosis and the
clinical management of disease.
We found that the association between a favorable outcome and dMMR status showed no
statistical significance for DFS and OS of the stage II cohort of patients. However, 5-FU che-
motherapy tended towards poorer prognosis for stage II patients with dMMR, a result that is
discordant with other previous studies [7,22]. Compared to stage III CRCs, more stage II
CRCs were with dMMR, especially the stage IIA tumors that had a higher dMMR rate of
16.6%. In our study, MMR status appeared to act as an independent prognostic biomarker for
DFS in patients with stage III colon cancer that had received adjuvant FOLFOX chemotherapy
a result that is consistent with other recent studies[6,23]. In metastatic CRC (mCRC), we
found that the prevalence of dMMR was low (4.9%). This finding supports the hypothesis that
dMMR tumors have a reduced metastatic potential. The low prevalence of dMMR in mCRC
could be explained by the reduced potential of stage I-III dMMR tumors to metastasize [24].
However the underlying mechanisms of this low metastatic potential are yet to be elucidated.
In terms of the prognostic value of dMMR in mCRC, our data showed no statistical difference
between dMMR versus the pMMR cohort of patients.
Although ERCC1 has a role as a prognostic marker in NSCLC[16], only a few studies have
evaluated its role as a prognostic marker in colorectal cancer and most of the previous data
were generated in the metastatic setting of cancer[13,14,15]. In this current study, we have
found that Chinese CRC patients with ERCC1 expression have a significantly better prognosis
than the negative cohort group with stage II and III disease. However, our data showed no sta-
tistical difference between ERCC1 positive and negative cohorts of patients that had stage I or
IV disease indicating other factors are also involved in the pathogenesis of the disease. While a
report on NSCLC patients found that ERCC1 expression was significantly lower in female
than male cancer patients, our study did not find any significant differences in sex, tumor loca-
tions, pathological differentiation, substages or ages for ERCC1 expression.
Finally, our large dataset showed that patients with pMMR status tended to also have posi-
tive ERCC1 expression, suggesting a collaboration of these two DNA repair pathways in main-
taining cell integrity and normalcy. MMR proteins are responsible for correcting mismatched
nucleotides and insertion-deletion loops (IDLs) in DNA caused by polymerase errors, chemi-
cal modifications, and recombination between heterologous DNA sequences[7], while ERCC1
is a key molecule in the nucleotide excision repair (NER) pathway, which is responsible for
repairing DNA adducts induced by platinum drugs[14,15]. The underlying mechanisms of
these potential interactions between these DNA repair proteins still needs to be elucidated to
gain a better understanding of CRC pathogenesis and its prognosis.
Conclusion
Our study is the first big dataset research following the recommendation of “The Evaluation of
Genomic Applications in Practice of Prevention” (EGAPP) since 2011. Our results provide
Screening for MMR and ERCC1 in CRC
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cutting-edge insights for the evaluation of the significance of MMR status for the prognosis
and treatment of CRC. Moreover, it is also the first persuasive study showing the correlation
between MMR status and ERCC1 expression. Hence, further research about the correlation of
the pathway of mismatch repair and nucleotide-excision repair is needed.
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